Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design

PLoS Pathogens

Volumn 13, Issue 2, 2017, Pages

  Irimia, Adriana ^a   Serra, Andreia M ^a   Sarkar, Anita ^a   Jacak, Ronald ^a,b   Kalyuzhniy, Oleksandr ^a   Sok, Devin ^a   Saye Francisco, Karen L ^a   Schiffner, Torben ^a   Tingle, Ryan ^a   Kubitz, Michael ^a   Adachi, Yumiko ^a   Stanfield, Robyn L ^a   Deller, Marc C ^a   Burton, Dennis R ^a,c   Schief, William R ^a,c   Wilson, Ian A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY APPLIED PHYSICS LABORATORY   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 41; NEUTRALIZING ANTIBODY; BLOCKING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIGEN ANTIBODY REACTION; ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIGHT SCATTERING; MODEL; MUTAGENESIS; MUTATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LIPID INTERACTION; SIZE EXCLUSION CHROMATOGRAPHY; SURFACE PLASMON RESONANCE; VIRUS ENVELOPE; VIRUS MORPHOLOGY; VIRUS MUTANT; VIRUS NEUTRALIZATION; X RAY DIFFRACTION; CHEMISTRY; IMMUNOLOGY; PROTEIN CONFORMATION;

ANTIBODIES, BLOCKING; ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; PROTEIN CONFORMATION; SURFACE PLASMON RESONANCE; X-RAY DIFFRACTION;

EID: 85014097584     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006212     Document Type: Article

References (58)

1. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011; 477: 466–470. doi: 10.1038/nature1037321849977
2. Burton DR, Hangartner L, Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol. 2016; 34: 635–659. doi: 10.1146/annurev-immunol-041015-05551527168247
3. Zwick MB, The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. AIDS. 2005; 19: 1725–1737. 16227780
4. Dimitrov AS, Jacobs A, Finnegan CM, Stiegler G, Katinger H, et al. Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry. 2007; 46: 1398–1401. doi: 10.1021/bi062245f17260969
5. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol. 2004; 78: 10724–10737. doi: 10.1128/JVI.78.19.10724-10737.200415367639
6. Song L, Sun ZY, Coleman KE, Zwick MB, Gach JS, et al. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc Natl Acad Sci USA. 2009; 106: 9057–9062. doi: 10.1073/pnas.090147410619458040
7. Sun ZY, Oh KJ, Kim M, Yu J, Brusic V, et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity. 2008; 28: 52–63. doi: 10.1016/j.immuni.2007.11.01818191596
8. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, et al. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci USA. 2008; 105: 3739–3744. doi: 10.1073/pnas.080025510518322015
9. Rathinakumar R, Dutta M, Zhu P, Johnson WE, Roux KH, Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions. J Virol. 2012; 86: 1820–1831. doi: 10.1128/JVI.05489-1122090143
10. Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, et al. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J Virol. 2011; 85: 8217–8226. doi: 10.1128/JVI.00756-1121653673
11. Zhu P, Winkler H, Chertova E, Taylor KA, Roux KH, Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs. PLoS Pathog. 2008; 4: e1000203. doi: 10.1371/journal.ppat.100020319008954
12. Zhu P, Liu J, Bess J, Jr.Chertova E, Lifson JD, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature. 2006; 441: 847–852. doi: 10.1038/nature0481716728975
13. Zanetti G, Briggs JA, Grunewald K, Sattentau QJ, Fuller SD, Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog. 2006; 2: e83. doi: 10.1371/journal.ppat.002008316933990
14. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, et al. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 2010; 6: e1001249. doi: 10.1371/journal.ppat.100124921203482
15. Apellaniz B, Rujas E, Serrano S, Morante K, Tsumoto K, et al. The atomic structure of the HIV-1 gp41 transmembrane domain and its connection to the immunogenic membrane-proximal external region. J Biol Chem. 2015; 290: 12999–13015. doi: 10.1074/jbc.M115.64435125787074
16. Dev J, Park D, Fu Q, Chen J, Ha HJ, et al. Structural basis for membrane anchoring of HIV-1 envelope spike. Science. 2016; 353: 172–175. doi: 10.1126/science.aaf706627338706
17. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013; 342: 1477–1483. doi: 10.1126/science.124562524179159
18. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014; 514: 455–461. doi: 10.1038/nature1380825296255
19. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013; 342: 1484–1490. doi: 10.1126/science.124562724179160
20. Lee JH, Ozorowski G, Ward AB, Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science. 2016; 351: 1043–1048. doi: 10.1126/science.aad245026941313
21. Matyas GR, Beck Z, Karasavvas N, Alving CR, Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta. 2009; 1788: 660–665. doi: 10.1016/j.bbamem.2008.11.01519100711
22. Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR, Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci USA. 2010; 107: 1529–1534. doi: 10.1073/pnas.090968010720080706
23. Irimia A, Sarkar A, Stanfield RL, Wilson IA, Crystallographic identification of lipid as an integral component of the epitope of HIV broadly neutralizing antibody 4E10. Immunity. 2016; 44: 21–31. doi: 10.1016/j.immuni.2015.12.00126777395
24. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA. 2009; 106: 20234–20239. doi: 10.1073/pnas.090871310619906992
25. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012; 491: 406–412. doi: 10.1038/nature1154423151583
26. Cardoso RM, Brunel FM, Ferguson S, Zwick M, Burton DR, et al. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol. 2007; 365: 1533–1544. doi: 10.1016/j.jmb.2006.10.08817125793
27. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity. 2005; 22: 163–173. doi: 10.1016/j.immuni.2004.12.01115723805
28. Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schulke N, et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol. 2001; 75: 10906–10911. doi: 10.1128/JVI.75.22.10906-10911.200111602730
29. Julien JP, Bryson S, Nieva JL, Pai EF, Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J Mol Biol. 2008; 384: 377–392. doi: 10.1016/j.jmb.2008.09.02418824005
30. Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, et al. A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol. 2009; 83: 8451–8462. doi: 10.1128/JVI.00685-0919515770
31. Chen J, Frey G, Peng H, Rits-Volloch S, Garrity J, et al. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol. 2014; 88: 1249–1258. doi: 10.1128/JVI.02664-1324227838
32. Xu H, Song L, Kim M, Holmes MA, Kraft Z, et al. Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J Virol. 2010; 84: 1076–1088. doi: 10.1128/JVI.02113-0919906921
33. Guenaga J, Wyatt RT, Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function. PLoS Pathog. 2012; 8: e1002806. doi: 10.1371/journal.ppat.100280622829767
34. Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol. 2010; 84: 2955–2962. doi: 10.1128/JVI.02257-0920042512
35. Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure. 2010; 18: 1116–1126. doi: 10.1016/j.str.2010.06.01020826338
36. Brugger B, Glass B, Haberkant P, Leibrecht I, Wieland FT, et al. The HIV lipidome: a raft with an unusual composition. Proc Natl Acad Sci USA. 2006; 103: 2641–2646. doi: 10.1073/pnas.051113610316481622
37. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010; 84: 1439–1452. doi: 10.1128/JVI.02108-0919939925
38. Kwon YD, Georgiev IS, Ofek G, Zhang B, Asokan M, et al. Optimization of the solubility of HIV-1-neutralizing antibody 10E8 through somatic variation and structure-based design. J Virol. 2016; 90: 5899–5914. doi: 10.1128/JVI.03246-1527053554
39. Brooks BR, Brooks CL, 3rdMackerell AD, Jr.Nilsson L, Petrella RJ, et al. CHARMM: the biomolecular simulation program. J Comput Chem. 2009; 30: 1545–1614. doi: 10.1002/jcc.2128719444816
40. Tran EE, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 2012; 8: e1002797. doi: 10.1371/journal.ppat.100279722807678
41. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol. 2007; 178: 4424–4435. 17372000
42. Chen Y, Zhang J, Hwang KK, Bouton-Verville H, Xia SM, et al. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J Immunol. 2013; 191: 1260–1275. doi: 10.4049/jimmunol.130077023825311
43. Doyle-Cooper C, Hudson KE, Cooper AB, Ota T, Skog P, et al. Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J Immunol. 2013; 191: 3186–3191. doi: 10.4049/jimmunol.130128523940276
44. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005; 308: 1906–1908. doi: 10.1126/science.111178115860590
45. Singh H, Henry KA, Wu SS, Chruscinski A, Utz PJ, et al. Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies. AIDS. 2011; 25: 1247–1257. doi: 10.1097/QAD.0b013e32834785cf21508803
46. van Meer G, Voelker DR, Feigenson GW, Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008; 9: 112–124. doi: 10.1038/nrm233018216768
47. Lorizate M, Sachsenheimer T, Glass B, Habermann A, Gerl MJ, et al. Comparative lipidomics analysis of HIV-1 particles and their producer cell membrane in different cell lines. Cell Microbiol. 2013; 15: 292–304. doi: 10.1111/cmi.1210123279151
48. Aloia RC, Tian H, Jensen FC, Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci USA. 1993; 90: 5181–5185. 8389472
49. Paruch S, Heinis M, Lemay J, Hoeffel G, Maranon C, et al. CCR5 signaling through phospholipase D involves p44/42 MAP-kinases and promotes HIV-1 LTR-directed gene expression. FASEB J. 2007; 21: 4038–4046. doi: 10.1096/fj.06-7325com17627030
50. Soto C, Ofek G, Joyce MG, Zhang B, McKee K, et al. Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. PLoS One. 2016; 11: e0157409. doi: 10.1371/journal.pone.015740927299673
51. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005; 79: 10108–10125. doi: 10.1128/JVI.79.16.10108-10125.200516051804
52. Otwinowski Z, Minor W, Processing of X-ray diffraction data collected in oscillation mode. Meth Enzymol. 1997; 276: 307–326.
53. Kabsch W, XDS. Acta Crystallogr D Biol Crystallogr. 2010; 66: 125–132. doi: 10.1107/S090744490904733720124692
54. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. Phaser crystallographic software. J Appl Crystallogr. 2007; 40: 658–674. doi: 10.1107/S002188980702120619461840
55. Emsley P, Lohkamp B, Scott WG, Cowtan K, Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010; 66: 486–501. doi: 10.1107/S090744491000749320383002
56. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010; 66: 213–221. doi: 10.1107/S090744490905292520124702
57. The PyMOL molecular graphics system version 1.3, Schrödinger, LLC.
58. Jo S, Kim T, Im W, Automated builder and database of protein/membrane complexes for molecular dynamics simulations. PLoS One. 2007; 2: e880. doi: 10.1371/journal.pone.000088017849009